Research Topics
| Loveleen BansiSummaryAffiliation: University College London Country: UK Publications
| Collaborators
|
Detail Information
Publications
Are previous treatment interruptions associated with higher viral rebound rates in patients with viral suppression?Loveleen K Bansi
Department of Primary Care and Population Sciences, Royal Free and University College Medical School, Hampstead Campus, Rowland Hill Street, London, NW3 2PF, UK
AIDS 22:349-56. 2008..We investigated whether previous treatment interruptions are associated with a raised risk of viral rebound in individuals who have attained virological suppression...
Impact of transmitted drug-resistance on treatment selection and outcome of first-line Highly Active Antiretroviral Therapy (HAART)Loveleen Bansi
HIV Epidemiology nad Biostatistics Group, Research Department of Infection and Population Health, Division of Population Health, Hampstead Campus, University College Medical School, University College London, Rowland Street, NW3 2PF, London, United Kingdom
J Acquir Immune Defic Syndr 53:633-9. 2010..The study aim was to determine how resistance testing influences outcome of first-line highly active antiretroviral therapy (HAART) in routine practice in the United Kingdom...- Is 1 alanine transaminase >200 IU enough to define an alanine transaminase flare in HIV-infected populations? A new definition derived from a large cohort studyLoveleen Bansi
Research Department of Infection and Population Health, University College London Medical School, London, UK
J Acquir Immune Defic Syndr 52:391-6. 2009..However, the definition of an ALT flare is arbitrary and the extent to which such increases represent normal fluctuations has not been explored... - Virological response to initial antiretroviral regimens containing abacavir or tenofovirLoveleen Bansi
Research Department of Infection and Population Health, University College Medical School, Royal Free Campus, London, United Kingdom
J Infect Dis 200:710-4. 2009..88 for the interaction between pre-HAART viral load and nucleoside started). Likewise, there was no difference in rates of virological failure between the 2 drugs at 24-48 weeks after starting HAART... - Trends over calendar time in antiretroviral treatment success and failure in HIV clinic populationsL Bansi
UCL Medical School, Royal Free Campus, London, UK
HIV Med 11:432-8. 2010..Effective antiretroviral therapy (ART) has transformed the care of people with HIV, but it is important to monitor time trends in indicators of treatment success and antic future changes... - Data linkage reduces loss to follow-up in an observational HIV cohort studyTeresa Hill
Research Department of Infection and Population Health, UCL Medical School, London, UK
J Clin Epidemiol 63:1101-9. 2010..To ascertain the degree of loss to follow-up in a cohort and to identify its predictors... 
Factors influencing lopinavir and atazanavir plasma concentrationWolfgang Stöhr
MRC Clinical Trials Unit, London, UK
J Antimicrob Chemother 65:129-37. 2010..The aim of this study was to evaluate which demographic factors and concomitant drugs are associated with lopinavir and atazanavir plasma concentration...- Outcomes in the first year after initiation of first-line HAART among heterosexual men and women in the UK CHIC StudyTristan J Barber
St Stephen s AIDS Trust Clinical Trials Unit, Chelsea and Westminster NHS Foundation Trust, London, UK
Antivir Ther 16:805-14. 2011..We analysed the influence of gender on use and outcomes of first-line HAART in a UK cohort... - Risk of extensive virological failure to the three original antiretroviral drug classes over long-term follow-up from the start of therapy in patients with HIV infection: an observational cohort studyAndrew N Phillips
Department of Primary Care and Population Sciences, Royal Free and University College Medical School, London, UK
Lancet 370:1923-8. 2007..We estimated the proportion of patients who had extensive triple-class failure during long-term follow-up and examined characteristics associated with an increased rate of failure... - Biomarkers to monitor safety in people on art and risk of mortalityLoveleen Bansi
UCL Medical School, Royal Free Campus, London, UK
J Acquir Immune Defic Syndr 60:51-8. 2012..Using time-updated laboratory measurements, we use several methods to derive a score that can be used to identify individuals at high risk of mortality... - HIV-associated central nervous system diseases in the recent combination antiretroviral therapy eraLucy Garvey
Clinical Trials Centre, Winston Churchill Wing, St Mary s Hospital, London, W2 1NY, UK
Eur J Neurol 18:527-34. 2011..Data describing the incidence and survival of HIV-related central nervous system diseases (CNS-D) in recent years are sparse... - Discordant responses on starting highly active antiretroviral therapy: suboptimal CD4 increases despite early viral suppression in the UK Collaborative HIV Cohort (UK CHIC) StudyR J C Gilson
Centre for Sexual Health and HIV Research, Research Department of Infection and Population Health, University College London, The Mortimer Market Centre, Camden Primary Care Trust, London, UK
HIV Med 11:152-60. 2010..This study was designed to determine the incidence of a discordant response at two time-points, soon after 6 months and at 12 months, and to determine the relationship with clinical outcomes... - Frequency and patterns of protease gene resistance mutations in HIV-infected patients treated with lopinavir/ritonavir as their first protease inhibitorTristan J Barber
Medical Research Council Clinical Trials Unit, St Stephen s Centre, Chelsea and Westminster Hospital, 125 Kingsway, London, UK
J Antimicrob Chemother 67:995-1000. 2012..Scarce data exist from long-term cohorts on resistance incidence or mutational patterns emerging to different PIs... - The impact of HIV drug resistance testing on changes to treatmentLoveleen Bansi
Research Department of Infection and Population Health, UCL Medical School, UK
AIDS 25:603-10. 2011..We investigate changes made to therapy after a resistance test result and identify factors associated with switching regimen... - Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and co-medicationWolfgang Stöhr
MRC Clinical Trials Unit, London, UK
Antivir Ther 13:675-85. 2008..The aim of this study was to examine factors influencing plasma concentration of efavirenz and nevirapine... - Late diagnosis in the HAART era: proposed common definitions and associations with mortalityCaroline A Sabin
Research Department of Infection and Population Health, UCL Medical School, London, UK
AIDS 24:723-7. 2010.... - CD4 counts and the risk of systemic non-Hodgkin's lymphoma in individuals with HIV in the UKMark Bower
Research Department of Infection and Population Health, Division of Population Health, UCL Medical School, Royal Free Campus, Rowland Hill Street, London, NW3 2PF, UK
Haematologica 94:875-80. 2009..Earlier highly active anti-retroviral therapy initiation and wider access to HIV testing is advocated to reduce the risk of systemic non-Hodgkin's lymphoma... - The associations between age and the development of laboratory abnormalities and treatment discontinuation for reasons other than virological failure in the first year of highly active antiretroviral therapyC A Sabin
Department of Primary Care and Population Science, Royal Free and UC Medical School, London, UK
HIV Med 10:35-43. 2009.... - The effect of transmitted HIV-1 drug resistance on pre-therapy viral loadLinda Harrison
HIV and Infections Group, MRC Clinical Trials Unit, London, UK
AIDS 24:1917-22. 2010..Reduced replication capacity of viruses expressing drug resistant mutations implies that patients with transmitted drug resistance (TDR) could have lower HIV RNA viral load than those infected with wild-type virus... - Treatment switches during pregnancy among HIV-positive women on antiretroviral therapy at conceptionSusie E Huntington
UCL Medical School, Royal Free Campus, UK
AIDS 25:1647-55. 2011.... - Second-line protease inhibitor-based antiretroviral therapy after non-nucleoside reverse transcriptase inhibitor failure: the effect of a nucleoside backboneLaura Waters
Department of GU HIV Medicine, Mortimer Market Centre, London, UK
Antivir Ther 18:213-9. 2013..We investigated the effect of an NRTI backbone in individuals receiving PI/r after failing NNRTI-based combined antiretroviral therapy... - Hepatitis B virus infection in HIV-positive individuals in the UK collaborative HIV cohort (UK CHIC) studyHuw Price
Centre for Sexual Health and HIV Research, Research Department of Infection and Population Health, University College London, London, United Kingdom
PLoS ONE 7:e49314. 2012..This study aimed to determine the prevalence and incidence of HBV in the UK CHIC Study, a multicentre observational cohort... - Clinical epidemiology of HIV-associated end-stage renal failure in the UKLoveleen Bansi
University College London Medical School, London, UK
AIDS 23:2517-21. 2009..To describe the clinical epidemiology of HIV-associated end-stage renal failure (HIV/ESRF) from 1998 to 2007 in the United Kingdom... - Outcome in renal Al amyloidosis after chemotherapyJennifer H Pinney
National Amyloidosis Centre, Division of Medicine, University College London Medical School, Rowland Hill St, London NW3 2PF, United Kingdom
J Clin Oncol 29:674-81. 2011..The purpose of this study was to evaluate the effect of chemotherapy on clinical outcome among patients with renal AL amyloidosis...